AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04473742 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample
Description: 2 drying tubes for 12 mL blood collection
Study NCT04473742 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: 1 drying tube for 6 mL blood collection
Study NCT05111301 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control-IQ technology 1.5
Description: All subjects wearing the t-slim X2 insulin pump with Control-IQ technology 1.5, and wearing the Dexcom G6 sensor.~Outcomes will be analyzed overall and subgroup analysis will be performed by Group, and by baseline A1c level.
Study NCT04951661 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Participants will be set up in the VR equipment. They will engage and follow along with a 10-20 minute guided meditation through the VR. The meditation program may include simulated movement, relaxing music, and the voice of a meditation guide. The research team member will supervise the session, ensuring safety of the subject is maintained.
Study NCT04838977 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RESET
Description: Therapy
Study NCT05344404 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide Riboside
Description: 3000mg total daily. Administered in capsule form in doses of 1500mg twice daily for the duration of the trial (4 weeks).
Study NCT05344404 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drug. Administered in tablet form twice daily for the duration of the trial (4 weeks).
Study NCT05317325 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OCDC vaccine; NeoDC vaccine
Description: OCDC vaccine and NeoDC vaccine are administered in a prime-boost regimen by subcutaneous injection.
Study NCT05751018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: Pyrotinib maleate is a small molecule tyrosine kinase inhibitor that can irreversibly inhibit HER1, HER2, and HER4.
Study NCT04882397 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instrument Assisted Soft Tissue Mobilization
Description: Bilateral Instrument assisted soft tissue mobilization application will be applied in a single session to the trapezius and sternocleideomastoideus muscles.
Study NCT05282602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: baseline physical therapy treatment along with Wii Fit based exercises
Description: Group A performed Wii Fit based exercises for 6 weeks. Group A will be treated with Wii Fit based exercises (40 mins session, 3 days/week, Penguin slide, soccer heading, tilt table, tightrope walking)
Study NCT05282602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive exercises
Description: Group B will be treated with Proprioceptive training (40 min session, 3 days/week, toe walking, heel walking, cross-body leg swings right and left sides, partial squat, ). In both groups pre and post-test measurements of Balance and Fall of risk will be assessed through Berg Balance scale, STAR excursion, Modified Fall Efficacy scale, and Timed Up and Go (TUG). Evaluation will be done before session start and at the end of 6th Week.
Study NCT05089422 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Squint surgery
Description: Lateral rectus recession and /or medial rectus resection
Study NCT05867329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine Injection (IV)
Description: Drug be administered as weight-based continuous infusion (2mg/kg/day) during the second stage of treatment (if applicable).~Cyclosporine monitoring will take place approximately 18-24 hours stage of treatment (Day 4 at the earliest). The goal is to achieve whole blood levels of 300 (range 200-400) ng/ml with adjustments according to the table in the protocol. The intravenous cyclosporine dosage is rarely raised above 4 mg/kg/day, in rare patients that are fast metabolizers.
Study NCT05867329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine Oral Product
Description: Once participants meet discharge criteria, participant's that received IV Cyclosporine (stage 2) will be transitioned to oral Cyclosporine.~The oral dose is calculated to be approximately twice the daily intravenous dose or approximately 5 mg/kg, rounded to nearest 25 mg, and is administered every 12 hours (h). Oral cyclosporine solution will be administered as Sandimmune capsules available in 25mg 100mg capsules size.~After the intervention period (during hospitalization after IV cyclosporine is complete) and during the follow-up period any cyclosporine adjustments are permissible under the current study protocol according to the discretion of the treating physician.
Study NCT05867329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib Extended Release Oral Tablet
Description: This will be administered orally once daily as 45mg (stage one) or twice daily as a 30mg oral tablet (first stage and second stage) of treatment (if applicable).~Upon discharge a patient will be switched from Upadacitinib 30mg twice daily to 45mg daily for 8 weeks followed by 30mg or 15mg subsequently if Upadacitinib is to be continued after discharge. The choice of induction/maintenance agent initiated after discharge will be determined by inpatient treatment team and in consultation with the outpatient gastroenterologist. No patient will continue Upadacitinib 30mg twice daily after discharge from the hospital.
Study NCT05867329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Methylprednisolone
Description: Drug will be administered as 30mg twice daily during the first stage of treatment (if applicable) and through the second stage of treatment (if applicable). Prior to discharge a patient will be switched from IV Methylprednisolone to prednisone 40-60mg with plans to taper by 5mg/week (dose subject to adjustment by treating inpatient team and in consultation with the outpatient gastroenterologist).
Study NCT05867329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone Oral Product
Description: Patients that received IV Methylprednisolone will be switched prior to discharge from IV Methylprednisolone to prednisone 40-60mg with plans to taper by 5mg/week (dose subject to adjustment by treating inpatient team and in consultation with the outpatient gastroenterologist).
Study NCT06044051 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: An additionnal volume of blood will be collected at inclusion and at each follow-up visit
Study NCT06044051 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Expectoration
Description: Expectoration will be collected at inclusion and at each follow-up visit
Study NCT06044051 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nasopharyngeal swab
Description: A nasopharyngeal swab will be collected at inclusion and at each follow-up visit after an induced sputum
Study NCT06111118 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ThermaCare HeatWraps
Description: ThermaCare HeatWraps application
Study NCT06151080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide combined with G-CHOP (LO CHOP)
Description: Lenalidomide combined with G-CHOP to treat newly diagnosed diffuse large B-cell lymphoma with follicular lymphoma (CDLBCL-FL)
Study NCT04882397 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Bilateral sham Instrument assisted soft tissue mobilization application will be applied in a single session to the trapezius and sternocleideomastoideus muscles.
Study NCT05798260 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Agilent Seahorse XF Cell Mito Stress Test
Description: The Agilent Seahorse XF Cell Mito Stress Test measures key parameters of mitochondrial function by directly measuring the oxygen consumption rate (OCR) of cells on the Seahorse XFe and XF Extracellular Flux Analyzers. It is a plate-based live cell assay that allows to monitor spare respiratory capacity (SRC), basal respiration, ATP production-coupled respiration, maximal respiration, and non-mitochondrial respiration in real time before and after ketone monoester
Study NCT05035602 — intervention group
Intervention type: OTHER
Intervention: Physical activity assessment
Description: Physical activity patterns will be obtained from google location history, using an Android phone
Study NCT05831683 — intervention group
Intervention type: OTHER
Intervention: Introduction of Standard Operating Procedure regarding lung protective ventilation during general anaesthesia.
Description: The Standard Operating Procedure document will be introduced. The SOP document will cover the theoretical background, definition, and recommendations/criteria of LPV. The SOP document will reflect the most recent LPV guidelines.
Study NCT00910156 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Airtraq laryngoscope
Description: Airtraq intubation
Study NCT00910156 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glidescope laryngoscope
Description: glidescope intubation
Study NCT00910156 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh laryngoscope
Description: Macintosh intubation
Study NCT05744739 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT05744739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tomivosertib
Description: Given PO
Study NCT05713149 — intervention group
Intervention type: OTHER
Intervention: Surgical flap and anti-bacterial agents
Description: Surgical flap and anti-bacterial agents
Study NCT05787548 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contact information
Description: Information on how to contact Geisinger if the patient needs care
Study NCT05787548 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Urgent care map
Description: A map of the patient's nearest Geisinger urgent care location, with information about urgent care
Study NCT05787548 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-triage chart
Description: A chart demonstrating what to do in response to several common conditions where the patient might be compelled to visit the ED
Study NCT05693012 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: cfDNA methylation assessment
Description: An exploratory study to establish the early detection and prognosis models of multiple myeloma patients in China based on plasma cf DNA methylation assessment
Study NCT05637528 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Patients will undergo an MRI and mammography one year after MagTrace injections
Study NCT05140720 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PNEUMOSIL®
Description: Study subjects will be vaccinated PNEUMOSIL® with the primary doses as described below:~Group 1: 3 doses, 4 to 8 week interval Group 2: 2 doses, dose interval > 1 month Group 3: 2 doses, dose interval > 2 months
Study NCT06225479 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: An individualized 12-week exercise intervention that will follow American College of Sports Medicine guidelines to ensure a gradual safe increase in frequency and intensity. The exercise goals for participants in the intervention arm are to increase minutes/week of aerobic exercise, build strength and muscle mass, and improve flexibility, core strength, and balance progressively over the course of 12 weeks. The participants are prescribed 3 sessions of aerobic exercise lasting 45-75 minutes each, including warm up and cool down; 2 resistance training sessions per week, and at least 3 flexibility and balance sessions per week.~Intervention arm receives the following: Control arm Successful Aging newsletter plus additional educational materials related to exercise, heart rate monitor and resistance bands, and two 90-minute sessions and ten 30-minute phone sessions over 12 weeks with an exercise coach (the first two sessions include a resistance training session).
Study NCT06225479 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Calls and Newsletter
Description: A 12-week remote health education program developed by the study team to provide a control for the exercise intervention. Participants in this arm will receive a summary of the American College of Sports Medicine guidelines (self-directed and time-based), a twice-monthly Successful Aging newsletter with suggestions for health diet, stress reduction, and social engagement, and twice-monthly phone calls to reinforce and discuss topics in the newsletter and to review adverse events and change in medications.
Study NCT06227793 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pharmaceutical intervention
Description: Individuals randomized to the intervention group will undergo monthly pharmaceutical consultations for health education, initiated after randomization. There will be three in-person consultations, starting in month 1 with monthly spacing, scheduled by the pharmacist in the office, except for the first consultation, which will be scheduled by the pharmacist over the phone after randomization. These consultations will be part of the intervention study's educational process and will take place between the initial and final assessments. The educational process scripts for each consultation include a pharmaceutical follow-up form and an inhalation technique assessment form. Once the consultation is completed, the patient will also receive, via WhatsApp and/or email according to their preference, an educational video demonstrating the step-by-step inhalation technique based on their prescribed treatment.
Study NCT06384118 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Impact of an IMB theory-based health education intervention on hypoglycemic coping in patients with type 2 diabetes: a pilot study
Description: Based on IMB health education theory Questionnaire collection, face-to-face interview, and manual interpretation on the first day of admission; questionnaire collection, face-to-face interview, and manual interpretation on the first day of admission; hypoglycemia knowledge promotion on the second day; Peer experience sharing on the third day; access to WeChat group and knowledge pushing on the fourth day; hypoglycemia-related lectures and practical teaching on the fifth day, face-to-face teaching and development of blood glucose management plan. Hypoglycemia knowledge contest on the day before discharge; One week, two weeks and three weeks after discharge for WeChat push or phone call; WeChat push, phone call and questionnaire.
Study NCT05904418 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Robot-assisted US Scan of the vertebra L1 to S1
Description: A standardized robot-assisted US-Scan of the vertebra L1 to the S1 is executed. The two probe trajectories are generated automatically by an optical camera or RedGreenBlue-Depth (RGB-D) camera. Then the robot will scan at two mm/s, automatically following the trajectory. A 6 degrees of freedom (DoF) force sensor (Nano25, Ati Industrial Automation Inc.) was assembled at the US probe. During the scanning, it measures the interaction force and torque between the US probe and volunteers' skin to ensure volunteer safety. The US images and corresponding robot poses are recorded for the reconstruction. A previously developed algorithm is used to obtain a preliminary 3D reconstruction that will be used to adapt the scanning pattern in case of incomplete scanning.
Study NCT05904418 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Handheld US scan of the vertebra L1 to S1
Description: A handheld US-Scan of the vertebra L1 to S1 is executed. An optical marker for an Atracsys Camera is mounted to the US probe to track its position. Simultaneously, the optical tracking allows for standardization of the US-Scan through navigation. The acquired US images and corresponding poses are used to reconstruct the lumbar spines and compared to the ground truth (CT scan). Handheld US scanning will be performed at around two mm/s in two scanning trajectories. The US probe orientation will be adjusted during the scanning by comparing the optical marker orientation with the initial probe orientation. This combination leads to different scanning patterns. For each pattern, the scanning procedure will be repeated three times. At least once per volunteer, each handheld scanning pattern will be performed with a higher manual speed to assess the reconstruction quality with faster scanning. A graphical user interface (GUI) will synchronize and store the data during the scanning.
Study NCT05904418 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: ULD CT scan of the vertebra L1 to S1
Description: A ULD CT scan (CT, Siemens Naeotom Alpha: A-207883-62) of the lumbar spine (L1-S1) is performed at the Swiss Center for Musculoskeletal Imaging (SCMI) at Balgrist Campus, Zurich. The total duration estimate for the CT examination is 30 minutes, whereas the scan takes 15 minutes. The volunteers lie on their abdomen during this procedure to simulate the spine's position during the subsequent US examination. The vertebrae (L1-S1) in the CT Scans are manually segmented with global thresholding and the region growing tool in a standard segmentation software (Materialise Mimics, Leuven, Belgium). The 3D surface models are then exported as Standard Triangle Language (STL) files.
Study NCT05171062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bexmarilimab (FP-1305)
Description: standard 3+3 dose escalation trial of bexmarilimab (FP-1305)
Study NCT05171062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200mg IV is administered in 4 planned bexmarilimab dose escalation cohorts
Study NCT04820140 — intervention group
Intervention type: PROCEDURE
Intervention: Lymphatic drainage
Description: Lymphatic drainage
Study NCT05988606 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 15 minutes of high-intensity interval training
Description: Participants completed an 8 min warm-up and 1 round of high-intensity interval training
Study NCT05988606 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 43 minutes of high-intensity interval training
Description: Participants completed an 8 min warm-up and 5 rounds of high-intensity interval training
Study NCT05988606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hot environment
Description: Participants exercised in a hot environment, \~ 35 °C, \~40% relative humidity.
Study NCT05988606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Temperate environment
Description: Participants exercised in a temperate environment, \~ 22 °C, \~40% relative humidity.
Study NCT05952609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surefil One
Description: Ion-releasing restoration
Study NCT05952609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cention N
Description: Ion-releasing restoration
Study NCT05952609 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bulkfil resin composite
Description: resin composite (No ion-release)
Study NCT05996913 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imagery rescripting
Description: The current project aims to explore the feasibility of intervention featuring imagery rescripting (ImRs) and grounding in the management of somatic flashbacks amongst this population. ImRs was developed as a method to help activate a traumatic memory, bring corrective information into the memory, create a more favourable outcome to the memory and to support the participant to discover and express inhibited trauma-related emotional responses (Arntz \& Weertman, 1999).
Study NCT05600777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLU-5937
Description: Oral administration of BLU-5937 Tablets
Study NCT05600777 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of matching placebo for BLU-5937 Tablets
Study NCT05460091 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PTech Device
Description: High-frequency vibration device used on regular basis in orthodontics
Study NCT05460091 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: PTech Sham Device
Description: sham device (does not vibrate)
Study NCT05741554 — intervention group
Intervention type: OTHER
Intervention: Rate of myometrial involvement in the population of 28 low grade serous ovarian carcinoma.
Description: Presence of uterine myometrial metastasis at pathology examination after cytoreductive surgery
Study NCT05166837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSA-1002 injection
Description: Intravenous injection
Study NCT05166837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous injection
Study NCT05482750 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training in the fasted state
Description: On the first day of evaluations, the subjects will perform the basal metabolic rate (BMR) analysis, as well as familiarization with the neuromuscular tests. After the preliminary tests, the volunteers will perform the pre-intervention procedures. Assessments of body composition, muscle thickness and quality, maximum dynamic strength and maximum power will be performed. In addition, instruments related to dietary control and physical activity level will be applied. Subsequently, in a randomized manner, participants will be allocated to one of two different interventions. During the intervention (8 weeks), the adherence to the standard diet will be verified, as well as body composition, muscle thickness and quality, maximum dynamic strength and maximum power will be reassessed. After the 12 weeks of intervention, the volunteers will perform the evaluations referring to the post-intervention moment, following the same steps of the pre-intervention collections.